Streetbeat News

RAPP

Rapport Therapeutics Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

13.21

Mkt cap

464M

Volume

149K

High

13.24

P/E Ratio

-6.47

52-wk high

29.74

Low

12.53

Div yield

N/A

52-wk low

12.10

Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotech company, will present at two investor conferences in March 2025, including the TD Cowen 45th Annual Health Care Conference in Boston.

Portfolio Pulse from

February 24, 2025 | 12:15 pm

Rapport Therapeutics has presented data showing a strong correlation between reductions in long episodes and clinical seizures, supporting the potential of their drug RAP-219 for treating focal epilepsy. The ongoing Phase 2a trial's primary endpoint is the change in long episode frequency, with results expected in mid-2025.

Portfolio Pulse from

December 06, 2024 | 5:15 pm

Rapport Therapeutics is set to present data at the American Epilepsy Society Annual Meeting, including findings from a Phase 2a trial on seizure biomarkers, as well as preclinical and Phase 1 clinical data.

Portfolio Pulse from

November 14, 2024 | 12:15 pm

Several Wall Street analysts have initiated coverage on various stocks with positive ratings. Notably, PureCycle Technologies, ChoiceOne Financial Services, Rapport Therapeutics, Neonode, and Global Self Storage received Buy or Overweight ratings with significant price targets above their current trading prices.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 2:51 pm

Jones Trading has initiated coverage on Rapport Therapeutics with a Buy rating and set a price target of $42.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 1:01 pm

Rapport Therapeutics ended the quarter with $336.1 million in cash, cash equivalents, and short-term investments, excluding restricted cash. This funding is expected to support operations through the end of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:58 am

Rapport Therapeutics reported a Q2 2024 GAAP EPS of $(1.70), missing the estimate of $(0.68).

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:57 am

TD Cowen has initiated coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating, as announced by analyst Joseph Thome.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 2:12 pm

Jefferies has initiated coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 12:04 pm

Stifel analyst Paul Matteis initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and sets a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 9:55 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.